SAB Biotherapeutics, Inc. (SABSW) Stock Overview
Explore SAB Biotherapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
SAB Biotherapeutics, Inc. (SABSW)
Key Financials
Key Financials
Market Cap
10.5K
P/E Ratio
0.80
EPS (TTM)
$-0.37
ROE
-0.07%
SABSW Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of SAB Biotherapeutics, Inc. (NASDAQ: SABSW) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, SAB Biotherapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of SABSW on the NASDAQ shows an RSI of 22.13, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $0.23 for the NASDAQ listing.
Key metrics behind SAB Biotherapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of 0.80 and a market capitalization of 10.5K. Combined with our AI analysis, these give both institutional and retail investors a clear view of SABSW on the NASDAQ.